Benitec Biopharma Inc. (BNTC): Price and Financial Metrics

Benitec Biopharma Inc. (BNTC): $5.50

0.73 (-11.72%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add BNTC to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#207 of 353

in industry

BNTC Price/Volume Stats

Current price $5.50 52-week high $9.01
Prev. close $6.23 52-week low $1.86
Day low $5.31 Volume 38,000
Day high $6.25 Avg. volume 16,532
50-day MA $4.50 Dividend yield N/A
200-day MA $3.56 Market Cap 14.26M

BNTC Stock Price Chart Interactive Chart >


Benitec Biopharma Inc. (BNTC) Company Bio


Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.


BNTC Latest News Stream


Event/Time News Detail
Loading, please wait...

BNTC Latest Social Stream


Loading social stream, please wait...

View Full BNTC Social Stream

Latest BNTC News From Around the Web

Below are the latest news stories about BENITEC BIOPHARMA INC that investors may wish to consider to help them evaluate BNTC as an investment opportunity.

Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

Announcement marks the initiation of the first clinical trial conducted in human subjects employing Benitec’s “Silence and Replace” DNA-directed RNA interference gene therapy platformHAYWARD, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, tod

Yahoo | November 30, 2023

Here's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Compensation Is The Least Of Shareholders Concerns

Key Insights Benitec Biopharma will host its Annual General Meeting on 6th of December Total pay for CEO Jerel Banks...

Yahoo | November 30, 2023

Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec, will participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference on Thursday,

Yahoo | November 17, 2023

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

19 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry into the BB-301 Phase 1b/2a Clinical Treatment StudyHAYWARD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced financial res

Yahoo | November 13, 2023

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry into the BB-301 Phase 1b/2a Clinical Treatment Study Successful Closing of a $30.9 M Public Offering HAYWARD, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or

Yahoo | September 21, 2023

Read More 'BNTC' Stories Here

BNTC Price Returns

1-mo 7.84%
3-mo 87.71%
6-mo 59.88%
1-year 51.54%
3-year -93.03%
5-year -98.81%
YTD 70.28%
2023 11.76%
2022 -93.51%
2021 -12.67%
2020 -60.78%
2019 -66.00%

Continue Researching BNTC

Want to see what other sources are saying about Benitec Biopharma LTD's financials and stock price? Try the links below:

Benitec Biopharma LTD (BNTC) Stock Price | Nasdaq
Benitec Biopharma LTD (BNTC) Stock Quote, History and News - Yahoo Finance
Benitec Biopharma LTD (BNTC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!